FDA 483 - Life Line Stem Cell, Inc. - January 16, 2026
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Life Line Stem Cell, Inc. in New Haven, IN, was cited for multiple deficiencies during an FDA inspection of its HCT/P recovery operations. Observations included the failure to clearly identify quarantined HCT/Ps, lack of established temperature limits for HCT/P storage, and inadequate documentation for the verification of supplies and reagents. The firm also failed to follow its own procedures for equipment calibration, specifically for temperature monitoring devices.
ID · 53c84117-724a-42d0-b3c9-41e7d66de594